派格生物医药-B(02565.HK) 公布,集团自主研发的创新候选产品CR059相关研究摘要获美国糖尿病协会(ADA)2026年科学年会接收,并入选最新突破性摘要,将以海报形式展示。根据相关研究结果,CR059展现出显著减重效果、突出的降糖表现及长期表达特征,并显示出作为长效代谢疾病治疗方案的开发潜力。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-02 16:25。)...
Source Link派格生物医药-B(02565.HK) 公布,集团自主研发的创新候选产品CR059相关研究摘要获美国糖尿病协会(ADA)2026年科学年会接收,并入选最新突破性摘要,将以海报形式展示。根据相关研究结果,CR059展现出显著减重效果、突出的降糖表现及长期表达特征,并显示出作为长效代谢疾病治疗方案的开发潜力。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-02 16:25。)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.